Want to see AUPH full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.24Last Year’s EPS
0.16Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlights robust commercial momentum for LUPKYNIS with double-digit top-line growth, materially improved cash generation, a strong balance sheet and share repurchases. Management provided constructive 2026 guidance and disclosed promising early clinical results for aritinercept. Offsetting these positives are a significant one-time tax benefit that materially boosted reported net income, termination of a pediatric study (creating regulatory follow-up risk), emerging competition (Gazyva), limited near-term transparency on quarterly performance, and early-stage development uncertainties (ADAs). Overall, the positives—sustained product revenue growth, strong cash flow, and advancing pipeline—outweigh the headwinds, though some risks remain.Company Guidance
Strong LUPKYNIS Commercial Growth
Net product sales of LUPKYNIS for full year 2025 were $271.3M, up 25% year-over-year from $216.2M. Management reported LUPKYNIS sales grew 25% in 2025 and expects 2026 net product sales of $305M–$315M (up 12%–16% vs. 2025).
Quarterly Revenue and Sales Upside
Total revenue for Q4 2025 was $77.1M, up 29% from $59.9M in Q4 2024. Q4 net product sales of LUPKYNIS were $74.2M, up 29% from $57.6M in Q4 2024.
Substantial Improvement in Profitability and EPS
Reported net income for FY2025 was $287.2M (vs. $5.8M in 2024, up 4,852%) and diluted EPS was $2.07 (up 5,075% from $0.04). Q4 2025 diluted EPS was $1.53 (up 15,200% from $0.01).
Strong Cash Generation and Balance Sheet Actions
Cash flows from operating activities for FY2025 were $135.7M, up 206% from $44.4M in 2024; Q4 cash flow from ops was $45.7M, up 52% YoY. Cash, cash equivalents and investments totaled $398M (vs. $358.5M at 12/31/2024). Company repurchased 12.2M common shares for $98.2M, reducing fully diluted shares from 149.8M to 139.7M.
2026 Revenue Guidance Reflects Continued Growth
Company expects total revenue of $315M–$325M for 2026 (up 11%–15% vs. 2025) and net product sales of $305M–$315M (up 12%–16% vs. 2025), reflecting continued commercial momentum.
Promising Early-Stage Clinical Progress for Aritinercept
Aritinercept (dual BAFF–APRIL inhibitor) completed Phase I single-ascending-dose testing with good tolerability. Single doses produced robust, durable reductions in immunoglobulins supportive of once-monthly dosing. Company initiated a clinical study in one autoimmune indication and plans a second study in H1 2026; additional details expected in Q2 2026.
AUPH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AUPH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $16.25 | $15.14 | -6.80% |
Feb 26, 2026 | $14.43 | $13.97 | -3.19% |
Nov 04, 2025 | $13.17 | $14.27 | +8.35% |
Jul 31, 2025 | $9.05 | $9.24 | +2.15% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Aurinia Pharmaceuticals (AUPH) report earnings?
Aurinia Pharmaceuticals (AUPH) is schdueled to report earning on Jul 30, 2026, After Close (Confirmed).
What is Aurinia Pharmaceuticals (AUPH) earnings time?
Aurinia Pharmaceuticals (AUPH) earnings time is at Jul 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AUPH EPS forecast?
AUPH EPS forecast for the fiscal quarter 2026 (Q2) is 0.24.
